Compare L3Harris Technologies Inc (LHX) vs Mesoblast Limited (MESO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
L3Harris Technologies Inc vs Mesoblast Limited — how do they compare? L3Harris Technologies Inc trades at $280.26 (market cap $52.27B), while Mesoblast Limited trades at $16.28 (market cap $2.17B). The key difference: L3Harris Technologies Inc is far larger — about 24.1× Mesoblast Limited's market cap, and L3Harris Technologies Inc pays a 1.78% dividend while Mesoblast Limited pays none. Which is the better fit depends on your goals.
| LHX | MESO | |
|---|---|---|
Market Cap | $52.27B | $2.17B |
Sector | Industrials | Technology |
52-Week High | $378.48 | $20.96 |
52-Week Low | $263.09 | $12.88 |
Enterprise Value | $63.03B | $2.17B |
Dividend Yield | 1.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LHX trades at $280.57, down 0.51% today, with a bearish technical signal but strong fundamentals. The company reported Q1 2026 EPS of $2.72, beating estimates, and maintains robust cash flow. Recent contracts include a U.S. Space Force satellite deal and U.S. Army radio orders, supporting growth. Valuation metrics show a P/E of 30.62 and P/S of 2.36, with revenue rising to $21.87B in 2025.
Outlook is positive with a consensus price target of $367.50, implying 31% upside, driven by defense spending and execution. Risks include debt levels and geopolitical volatility. Analysts are 75% buy-rated, but technical indicators suggest near-term caution amid bearish moving averages.
MESO trades at $16.63, down 3.98% on the day, with a bullish technical outlook supported by moving averages. The company shows strong revenue growth with Ryoncil generating $115 million in annual revenue, though it remains unprofitable with a net loss of $102 million. Recent developments include positive Phase 3 trial progress and FDA BLA filings for new treatments.
Investment outlook balances promising pipeline progress against significant financial losses. The stock offers growth potential through commercial expansion but carries substantial risk from continued cash burn and regulatory hurdles. Analyst consensus leans bullish with 45% buy ratings, reflecting optimism about the company's transition to commercial-stage operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About L3Harris Technologies Inc
L3Harris Technologies was created in 2019 from the merger of L3 Technologies and Harris, two defense contractors that provide products for the command, control, communications, computers, intelligence, surveillance, and reconnaissance (C4ISR) market. The firm also has smaller operations serving the civil government, particularly the Federal Aviation Administration's communication infrastructure, and produces various avionics for defense and commercial aviation.
Read more on LHX →About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →
